Authors' reply

摘要

We agree with Markus Godel and Tobias Huber that the high rate of early primary endpoints in the ciclosporin group could reflect the haemodynamic and other nephrotoxic effects of that agent; but our aim was to examine in a "real world" trial the acceptability of that treatment approach. We stand by our conclusion:1 because patients treated with ciclosporin showed a further 20% decline in renal function (in addition to the 20% decline that had rendered them eligible for the trial), irrespective of the mechanism, this is not a desirable therapy in this group of patients.